Julia A. Haller - 05 Oct 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Director
Signature: /s/ Lawrence A. Kenyon, Attorney-in-Fact
Issuer symbol: OTLK
Transactions as of: 05 Oct 2022
Transactions value $: $0
Form type: 4
Filing time: 07 Oct 2022, 16:35:39 UTC
Previous filing: 04 Oct 2022
Next filing: 04 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLK	Stock Option (Right to Buy)	Award	$0	+42.2K		$0.00	42.2K	05 Oct 2022	Common Stock	42.2K	$1.25	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Content

The options were granted under the 2015 Plan in lieu of $44,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.